MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Ataxia: Treatment"

  • 2022 International Congress

    Therapies, Research Funding and Racial Diversity in Cerebellar Ataxia: A Systematic Review of the Literature

    C. Kingsbury, S. Ghanekar, Y. Huang, T. Ashizawa, S. Kuo, C. Gooch, T. Zesiewicz (Tampa, USA)

    Objective: To understand the scope of clinical research in cerebellar ataxia by performing a systematic review of controlled clinical trials over the past 50 years,…
  • 2022 International Congress

    Isolated ZIC4 antibody associated paraneoplastic cerebellar degeneration

    A. Agarwal, A. Garg, A. Srivastava (New Delhi, India)

    Objective: Anti-ZIC4 antibodies have recently been associated with paraneoplastic cerebellar degeneration (PCD) and are usually associated with small cell carcinoma lung. However, most of the…
  • 2022 International Congress

    Gene Expression Quantification to Assess Frataxin Replacement Therapies in Friedreich’s Ataxia

    M. Baile, D. Schecter, A. Miller, T. Galas, N. Scherer, R. Chen, N. Ruiz, D. Bettoun (Philadelphia, USA)

    Objective: To identify genetic disease and efficacy markers for Friedreich’s ataxia (FRDA) Background: FRDA is a genetic disease caused by decreased expression of the mitochondrial…
  • 2022 International Congress

    Leading Therapeutic Molecules Target Transcription Factors Binding to Repressor Region in FXN Gene

    V. Swarup, H. Singh, D. Gupta, I. Singh, A. Srivastava (New Delhi, India)

    Objective: To investigate interactions of transcription factors (TFs) binding to repressor region located upstream to FXN gene with leading therapeutic molecules. Background: Low levels of…
  • 2022 International Congress

    Tissue Frataxin Increases After Administration of CTI-1601, a Frataxin Replacement Therapy in Development for the Treatment of Friedreich’s Ataxia

    D. Bettoun, T. Galas, D. Schecter, N. Ruiz, R. Clayton, J. Farmer (Bala Cynwyd, USA)

    Objective: To evaluate the pharmacodynamic (PD) and safety profiles of subcutaneous (SC) administration of multiple ascending doses of CTI-1601 in patients age ≥18 years with…
  • MDS Virtual Congress 2021

    Cerebellar bioenergetic depletion following ubiquinol supplementation in a patient with COQ8A-related ataxia

    J. Prasuhn, M. Göttlich, B. Ebeling, C. Bodemann, S. Großer, I. Wellach, K. Reuther, H. Hanssen, N. Brüggemann (Lübeck, Germany)

    Objective: To non-invasively map the individual treatment response in a patient with COQ8A-related ataxia following coenzyme Q10 supplementation. Background: Primary coenzyme Q10 (CoQ10) deficiency is…
  • MDS Virtual Congress 2020

    A translational approach to determine target concentrations of MIN-102 (leriglitazone) to support a Phase II study in Friedreich’s ataxia

    S. Poli, L. Rodríguez-Pascau, J. Ros, P. González-Cabo, E. Britti, D. Lynch, G. Pina, S. Pascual, M. Cerrada-Gimenez, D. Eckland, E. Traver, J. Wetering-de-Rooij, M. Martinell, U. Meya, P. Pizcueta (Gosselies, Belgium)

    Objective: To determine efficacious plasma concentration of leriglitazone from preclinical models of Friedreich´s ataxia (FRDA). To confirm CNS target engagement in a first-in human study.…
  • MDS Virtual Congress 2020

    Feasibility and Acceptability of Lee Silverman Voice Treatment for patients with hereditary ataxia

    A.N. Lowit, A. Egan, M. Hadjivassiliou (Glasgow, United Kingdom)

    Objective: This study aimed to assess the feasibility and acceptability of Lee Silverman Voice Treatment (LSVT) provided via Skype for patients with hereditary ataxia. Background:…
  • MDS Virtual Congress 2020

    Effects of deep transcranial magnetic stimulation of the cerebellum on cerebellar ataxias: A randomized, double-blind, cross-over clinical trial

    C. França, D. de Andrade, V. Silva, R. Galhardoni, E. Barbosa, M. Teixeira, R. Cury (Sao Paulo, Brazil)

    Objective: To investigate whether cerebellar deep repetitive transcranial magnetic stimulation (d-rTMS) can improve ataxic symptoms when compared to sham stimulation. Background: Cerebellar ataxia remains a…
  • MDS Virtual Congress 2020

    A randomized, sham-controlled, crossover trial on Cerebello-Spinal Transcranial pulsed current stimulation (tPCS) in Ataxia

    J. Ganguly, D. Kulshreshtha, S. Soltani, Y. Krishnasamy Tamilselvam, O. Samotus, D. Aur, M. Jog (London, ON, Canada)

    Objective: Patients of degenerative cerebellar ataxia present with slurring of speech, imbalance during walking and problem of co-ordination in limbs.  Currently no effective treatment is…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley